Description

SAMβA TFA is conjugated to the cell permeable peptide TAT47-57. SAMβA TFA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C50H73N17O16.xC2HF3O2—-[1]Julio C B Ferreira A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats. Nat Commun. 2019 Jan 18;10(1):329.—-1168.22 (free acid)–98.91–OC(C(F)(F)F)=O.OC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(N)=N)N)=O)CC(N)=O)=O)C)=O)CCC(O)=O)=O)CC(N)=O)=O)=O)CC(O)=O)=O)CCCNC(N)=N)=O)CC2=CC=CC=C2)=O.[x]–Cardiovascular Disease–H2O : 50 mg/mL (ultrasonic)–PKC—-Epigenetics;TGF-beta/Smad–Peptides